Buisness Line
Business Daily from THE HINDU group of publicationsWednesday, Jan 10, 2007
Hyderabad, Jan. 9
Suven Life Sciences Ltd (SLSL) has obtained a European patent on a novel Serotonin Receptor Ligands, which are being developed as therapeutic agents soon.
The company announced today that the European Patent Office (EPO) issued the Patent 1517909 titled "Novel Tetracyclic Arylcarbonylindoles having Serotonin Receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them."
The patent would be valid until June 2023. The granted claims of the patent include the class of selective 5-HT compounds that would be useful in the treatment of cognitive impairment associated with neuro-degenerative disorders such as attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.
"We continue to work on G-Protein coupled receptor targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential," said Mr Venkat Jasti, CEO of the company.
http://www.blonnet.com/2007/01/10/stories/2007011003070300.htm
For any querry:-
09896868668
deepakmiglani@hotmail.com
No comments:
Post a Comment